Meeting
2020 Gastrointestinal Cancers Symposium
IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma.
Authors
Yehia I. Abugabal
University of Texas MD Anderson Cancer Center, Houston, TX
Yehia I. Abugabal , Aliya Qayyum , Manal Hassan , Lianchun Xiao , Dan G. Duda , Rikita Hatia , Sunyoung S. Lee , Robert A. Wolff , Roberto Pestana , Jeffrey Morris , James C. Yao , Hesham M. Amin , Ahmed Omar Kaseb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 488)
Abstract #
488
Poster Bd #
A13
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
IGF-Child-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.
First Author: Yehia I. Abugabal
Poster
2022 ASCO Annual Meeting
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin